Skip to content

ACT monitoring and calciumion monitoring guide citrate anticoagulation in patients with liver failure and renal failure for continuous renal replacement therapy: a single-center prospective randomized controlled trial

ACT monitoring and calciumion monitoring guide citrate anticoagulation in patients with liver failure and renal failure for continuous renal replacement therapy: a single-center prospective randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022784
Enrollment
Unknown
Registered
2019-04-25
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver and renal failure

Interventions

ACT monitoring group:ACT monitoring
Calcium ion monitoring group:Calcium ion monitoring

Sponsors

Beijing Ditan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 70 years. 2) Identify liver and kidney failure caused by various infections and require CRRT. 3) Patients with a CRRT time of more than 12 hours are expected.

Exclusion criteria

Exclusion criteria: 1) Patients with an expected survival time of less than 24 hours. 2) Patients with severe active bleeding within 48 hours prior to CRRT. 3) Patients with brain, eye, spine, and abdominal surgery within 72 hours before CRRT. 4) Malignant hypertension. 5) Patients with parathyroid disease.

Design outcomes

Primary

MeasureTime frame
Average amount of tannic acid;

Secondary

MeasureTime frame
48 hours filter life;Peripheral blood tCa2+/i Ca2+>2.5;

Countries

China

Contacts

Public ContactLi Ang

Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University

DTYYICU@GMAIL.COM+86 01084322678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026